---
title: "Wedbush Reaffirms Their Buy Rating on Cogent Biosciences (COGT)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295550630.md"
description: "Wedbush analyst David Nierengarten reaffirmed a Buy rating on Cogent Biosciences (COGT) with a $55 price target. This follows a recent Buy from LifeSci Capital, while Needham assigned a Hold rating to the stock today."
datetime: "2026-08-11T13:55:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295550630.md)
  - [en](https://longbridge.com/en/news/295550630.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295550630.md)
generator: "portal-rs"
---

# Wedbush Reaffirms Their Buy Rating on Cogent Biosciences (COGT)

Wedbush analyst David Nierengarten maintained a Buy rating on Cogent Biosciences today and set a price target of $55.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

According to TipRanks, Nierengarten is a 5-star analyst with an average return of 23.0% and a 54.93% success rate. Nierengarten covers the Healthcare sector, focusing on stocks such as Argenx Se, Damora Therapeutics, and Apogee Therapeutics.

In addition to Wedbush, Cogent Biosciences also received a Buy from LifeSci Capital’s Sam Slutsky in a report issued yesterday. However, today, Needham assigned a Hold rating to Cogent Biosciences (NASDAQ: COGT).

### Related Stocks

- [COGT.US](https://longbridge.com/en/quote/COGT.US.md)
- [ARGX.US](https://longbridge.com/en/quote/ARGX.US.md)
- [DMRA.US](https://longbridge.com/en/quote/DMRA.US.md)
- [APGE.US](https://longbridge.com/en/quote/APGE.US.md)

## Related News & Research

- [Analyst Reiterates Buy on Cogent Biosciences, Maintains $55 Price Target Amid Late-Stage Pipeline and Strong Cash Position](https://longbridge.com/en/news/296384188.md)
- [HC Wainwright Brokers Decrease Earnings Estimates for COGT](https://longbridge.com/en/news/296613212.md)
- [Research Analysts Set Expectations for COGT Q1 Earnings](https://longbridge.com/en/news/296480559.md)
- [Wedbush Keeps Their Buy Rating on IDEAYA Biosciences (IDYA)](https://longbridge.com/en/news/296510282.md)
- [Cogent Biosciences files for USD 400 million at-the-market stock offering](https://longbridge.com/en/news/295453309.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**